ONCAlert | Upfront Therapy for mRCC

Brain Cancer 1 MORE >>

Several presentations at the 2019 American Society of Clinical Oncology Annual Meeting highlighted a hopeful new direction in the treatment of gliomas, demonstrating the relevance of IDH1/2 mutational status and its feasibility as a target of therapy.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.